ArticleAnnals of surgical oncology2025
Contemporary Short-Term Outcomes of Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe roles and benefits of locoregional treatments in metastatic neuroendocrine tumors (NETs) need reassessment for contemporary decision making and counseling. We examined contemporary short-term outcomes of liver-directed therapy for metastatic NETs.
methodsWe conducted a population-based retrospective cohort study of patients with metastatic NETs (2000-2019) undergoing liver embolization or resection. Outcomes were 30-day major morbidity (Clavien-Dindo grade 3-5) and mortality. Logistic regression examined factors associated with outcomes in each group.
resultsOverall, 1054 patients underwent 1224 liver embolizations, and 502 liver resections were performed. Median length of hospital stay was 1 day (interquartile range [IQR] 1-4) for liver embolization and 7 days (IQR 5-9) for liver resection. Thirty-day major morbidity occurred in 10% of liver embolizations, including 40 (3.3%) deaths, and in 22.5% after liver resections, including 11 (2.2%) deaths. Factors independently associated with increased risk after liver embolization were prior embolization (odds ratio [OR] 0.64, 95% confidence interval [CI] 0.46-0.89) and combination of prior liver embolization and resection (OR 0.50, 95% CI 0.28-0.87). For liver resection, age >70 years was independently associated with increased odds of major morbidity (OR 2.08, 95% CI 1.12-3.84) and metachronous metastases with lower odds of major morbidity (OR 0.62, 95% CI 0.39-0.99).
conclusionIn this contemporary cohort, mortality after liver embolization was comparable with that after liver resection. Prior liver-directed therapy and older age were associated with higher risk of major morbidity This information is important when discussing the use and choice of liver-directed therapies and counseling patients with metastatic NETs.
Indexed as
Identifiers
40946123What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.